Zoetis Inc (NYSE:ZTS) – Investment analysts at Gabelli increased their FY2018 earnings per share (EPS) estimates for Zoetis in a report released on Tuesday, Zacks Investment Research reports. Gabelli analyst K. Kedra now anticipates that the company will earn $3.00 per share for the year, up from their previous forecast of $2.75. Gabelli also issued estimates for Zoetis’ FY2019 earnings at $3.45 EPS, FY2020 earnings at $3.85 EPS and FY2021 earnings at $4.30 EPS.
Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, November 2nd. The company reported $0.65 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.63 by $0.02. The firm had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.32 billion. Zoetis had a return on equity of 62.39% and a net margin of 18.29%. The business’s quarterly revenue was up 8.5% on a year-over-year basis. During the same period last year, the company posted $0.52 EPS.
Shares of Zoetis (NYSE:ZTS) traded up $1.47 on Wednesday, hitting $77.01. The stock had a trading volume of 1,520,000 shares, compared to its average volume of 1,960,000. The company has a debt-to-equity ratio of 2.45, a quick ratio of 1.95 and a current ratio of 2.80. The firm has a market cap of $37,530.00, a P/E ratio of 40.53, a PEG ratio of 1.90 and a beta of 1.06. Zoetis has a 12 month low of $52.00 and a 12 month high of $77.02.
A number of hedge funds have recently added to or reduced their stakes in ZTS. Northwestern Mutual Wealth Management Co. boosted its stake in Zoetis by 16.8% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock valued at $100,000 after purchasing an additional 230 shares during the last quarter. Steward Partners Investment Advisory LLC purchased a new position in shares of Zoetis in the 3rd quarter worth approximately $114,000. Harfst & Associates Inc. boosted its stake in shares of Zoetis by 16.1% in the 2nd quarter. Harfst & Associates Inc. now owns 1,878 shares of the company’s stock worth $117,000 after buying an additional 260 shares during the last quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its stake in shares of Zoetis by 251.9% in the 3rd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock worth $121,000 after buying an additional 1,360 shares during the last quarter. Finally, Shine Investment Advisory Services Inc. boosted its stake in shares of Zoetis by 86.5% in the 3rd quarter. Shine Investment Advisory Services Inc. now owns 2,242 shares of the company’s stock worth $143,000 after buying an additional 1,040 shares during the last quarter. Institutional investors and hedge funds own 93.14% of the company’s stock.
The business also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, January 19th will be paid a dividend of $0.126 per share. The ex-dividend date is Thursday, January 18th. This represents a $0.50 dividend on an annualized basis and a yield of 0.65%. This is an increase from Zoetis’s previous quarterly dividend of $0.11. Zoetis’s payout ratio is 22.11%.
WARNING: “Gabelli Research Analysts Boost Earnings Estimates for Zoetis Inc (ZTS)” was originally reported by BBNS and is the property of of BBNS. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://baseballnewssource.com/markets/zoetis-inc-zts-to-post-fy2018-earnings-of-3-00-per-share-gabelli-forecasts/1823197.html.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.